Remitch

PreclinicalSmall molecule

SShandong New Time Pharmaceutical Co., LTD

Remitch is one of 9 small molecule programs targeting Adverse Event. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EventRecruiting

HumansCompleted

Adverse EventPreclinical

Recruiting

HumansPreclinical

Completed

Competition

Competitive Landscape

11 competitors in Humans

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

1 2

Reboxetine

UUniversity of Zurich

Preclinical

1 3

Remitch

SShandong New Time Pharmaceutical Co., LTD

Preclinical

1 4

Astaxanthin

SSheba Medical Center

Preclinical

1 5

Salmonella Typhi

UUniversity of Oxford

Preclinical

1 6

Nalfurafine Hydrochloride

SShandong New Time Pharmaceutical Co., LTD

Preclinical

1 7

GLP-2

GGlostrup University Hospital, Copenhagen

Preclinical

1 8

Stool Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

PBR111

UUniversity of North Carolina, Chapel Hill

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Adverse Event

NCT07098351

Clinical

Trials by Indication[1]

Humans1 trial

Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans

Completed·SShandong New Time Pharmaceutical Co., LTD·N/A·NCT07478133·72 enrolled

Adverse Event1 trial

A Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Moderate to Severe Pruritus in Peritoneal Dialysis Patients

Recruiting·GGuangdong Provincial People's Hospital·Preclinical·NCT07098351·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Remitch. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remitch compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remitch. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong New Time Pharmaceutical Co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShandong New Time Pharmaceutical Co., LTD

Remitch

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Humans1 trial

Adverse Event1 trial

References

Drug Info

Quick Facts

Related News